Sarepta upgraded to Neutral from Sell at H.C. Wainwright
H.C. Wainwright upgraded Sarepta (SRPT) to Neutral from Sell with an unchanged price target of $75. The firm cites the stock’s current ...
Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to “Sector Perform” at Royal Bank of Canada
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...
Fierce Pharma3h
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
pharmaphorum23h
Capricor files cell therapy for DMD cardiomyopathy with FDA
Last year, Sarepta – which leads the market for exon-skipping DMD drugs – got FDA approval for Elevidys (delandistrogene moxeparvovec), the first gene therapy for the muscle-wasting disease.
Managed Healthcare Executive10h
New Study Shows Duchenne's Effect on the Brain Might Be Reversed
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...